CareDx (NASDAQ:CDNA) vs. Upstream Bio (NASDAQ:UPB) Head-To-Head Review

CareDx (NASDAQ:CDNA) and Upstream Bio (NASDAQ:UPB) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership and dividends.

Volatility and Risk

CareDx has a beta of 2.51, suggesting that its share price is 151% more volatile than the S&P 500. Comparatively, Upstream Bio has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500.

Profitability

This table compares CareDx and Upstream Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CareDx	25.86%	9.74%	7.35%
Upstream Bio	-4,955.67%	-48.40%	-46.57%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for CareDx and Upstream Bio, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CareDx	0	4	3	1	2.62
Upstream Bio	1	2	4	0	2.43

CareDx presently has a consensus price target of $64.40, suggesting a potential downside of 20.56%. Upstream Bio has a consensus price target of $29.67, suggesting a potential upside of 800.90%. Given Upstream Bio’s higher probable upside, analysts plainly believe Upstream Bio is more favorable than CareDx.

Valuation and Earnings

This table compares CareDx and Upstream Bio”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CareDx	$379.80 million	11.21	-$21.35 million	$2.39	33.92
Upstream Bio	$2.85 million	63.28	-$143.44 million	($2.90)	-1.14

CareDx has higher revenue and earnings than Upstream Bio. Upstream Bio is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

Summary

CareDx beats Upstream Bio on 10 of the 13 factors compared between the two stocks.

About CareDx

CareDx, Inc. is a precision medicine company focused on organ transplantation. It develops and provides diagnostic tests and related services to help clinicians assess transplant recipients and monitor their health over time. Its offerings include AlloSure, a donor-derived cell-free DNA test used to help monitor for organ rejection, and AlloMap, a gene-expression test used in heart transplant care. CareDx also provides histocompatibility testing, clinical tools, and services designed to support patients and transplant care teams.

About Upstream Bio

Upstream Bio, Inc. is a clinical-stage biotechnology company focused on developing therapies for inflammatory and immune-mediated diseases. The company’s research is centered on targeting pathways involved in type 2 inflammation, which contributes to conditions affecting the respiratory system and other tissues. Its lead product candidate is verekitug, an investigational, long-acting monoclonal antibody designed to block thymic stromal lymphopoietin (TSLP), an epithelial cytokine that plays a role in initiating and maintaining allergic and inflammatory responses.